TAS 114

Drug Profile

TAS 114

Alternative Names: TAS-114

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Dihydropyrimidine dehydrogenase inhibitors; DUTP pyrophosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 19 Sep 2017 Taiho Pharmaceutical plans the TAS114_GC phase II trial for Gastric cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Japan (UMIN000028329)
  • 01 Feb 2017 Taiho pharmaceutical completes a phase I trial in Solid tumours (Late stage disease, Combination therapy) in Japan (NCT01610479)
  • 29 Nov 2016 Adverse events, efficacy and pharmacokinetics data from a phase I trial in Solid tumours (Combination therapy) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top